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n 2012, cardiovascular disease accounted for 17.5 million deaths, nearly one-third of all deaths worldwide, and >80% (14.1 million) were from coronary artery disease (CAD) and stroke. CAD is preceded by cardiometabolic diseases (CMDs) such as hypertension, impaired lipid and glucose metabolism, and systemic inflammation (1, 2) . Genome-wide association studies (GWAS) have identified hundreds of DNA variants associated with risk for CAD (3), hypertension (4), blood lipid levels (5), markers of plasma glucose metabolism (6) (7) (8) (9) (10) , type 2 diabetes (6, 11), body mass index (12) , rheumatoid arthritis (13) , systemic lupus erythematosus (SLE) (14) , ulcerative colitis (15) , and Crohn's disease (16) . However, identifying susceptibility genes responsible for these loci has proven difficult.
GWAS loci typically span large, noncoding, intergenic regions with numerous single-nucleotide polymorphisms (SNPs) in strong linkage disequilibrium. These regions are enriched in cisregulatory elements (17) and expression quantitative trait loci (eQTLs) (18) (19) (20) , suggesting that gene regulation is the principal mechanism by which risk loci affect complex disease etiology. However, it is largely unknown whether this generegulatory effect includes one or several genes acting in one or multiple tissues and whether risk loci for different diseases share cis-and transgene regulation. A better understanding of gene regulation may also shed light on why known GWAS risk loci explain only~10% of expected heritable variance in CMD risk (21) . Possibly, multiple risk loci, acting through common cisand trans-genes, contribute synergistically to heritability (22, 23) .
In the Stockholm-Tartu Atherosclerosis Reverse Networks Engineering Task study (STARNET) ( fig. S1 ), we recruited 600 well-characterized (table S1 and fig. S2 ) CAD patients; genotyped DNA (6,245,505 DNA variant calls with minor allele frequency >5%) (fig. S3) ; and sequenced RNA isolated from blood, atherosclerotic-lesionfree internal mammary artery (MAM), atherosclerotic aortic root (AOR), subcutaneous fat (SF), visceral abdominal fat (VAF), skeletal muscle (SKLM), and liver (LIV) (15 to 30 million reads per sample) (figs. S4 to S11 and table S2).
In total,~8 million cis-eQTLs were identified, and nearly half were unique SNP-gene pairs (figs. S12 to S26 and tables S3 to S7). The STARNET cis-eQTLs were enriched in genetic associations established by GWAS for CAD, CMDs, and Alzheimer's disease (AD) (3-16, 24) (figs. S27 to S33) and were further enriched after epigenetic filtering (figs. S34 to S39). Of 3326 genome-wide significant-risk SNPs identified by GWAS to date (25), 2,047 (61%) had a matching cis-QTL in STARNET (Fig. 1A) . Of the 54 lead risk SNPs verified in meta-analyses of CAD GWAS (3), 38 ciseQTLs with a regulatory trait concordance score (RTC) >0.9 and at least one candidate gene were identified in STARNET (table S8 and fig. S27 ).
Compared with large data sets of cis-eQTL isolated only from blood, cis-eQTLs across all tissues in STARNET matched >10-fold more CAD and CMD-related GWAS risk SNPs (Fig. 1B) . STARNET cis-eQTLs isolated from CAD-affected tissues also matched several-fold more CAD and CMD-related GWAS risk SNPs than cis-eQTLs from corresponding tissues isolated from predominantly healthy individuals in the Genotype Tissue Expression (GTEx) study (18) (Fig. 1C) . Thus, not all gene-regulatory effects of disease-risk SNPs are identifiable in blood or healthy tissues. This notion was further underscored by comparing the statistical significances of cis-eQTLs for GWAS risk SNPs in STARNET with corresponding associations in GTEx (Fig. 1D ). In STARNET, gene fusions (table S9) and CAD-related loss of function mutations (table S10) were also detected.
The cis effects of disease-associated risk loci identified by GWAS are central for understanding downstream molecular mechanisms of disease. However, these cis-genes likely also affect downstream trans-genes. To identify possible trans effects, we ran a targeted analysis to call both cis-and trans-genes for lead risk SNPs identified by GWAS. After assigning cis-eQTLs for 562 risk SNPs for CAD, CMDs, and AD (3-16, 24), we used a causal inference test (26) to conservatively call causal correlations between the cis-genes and trans-genes by assessing the probability that an interaction was causal [SNP→cis-gene→trans-gene; false discovery rate (FDR) < 1%] and not reactive (SNP→trans-gene→cis-gene; P > 0.05) (26) (table S11). We found extensive sharing of cis-and trans-gene regulation by GWAS risk loci across tissues and CMDs. In CAD, 28 risk loci with at least one causal interaction (FDR < 1%, P > 0.05) had a total of 51 cis-genes and 1040 trans-genes. Of these, 26 risk loci, 37 cis-genes [including 27 key drivers (27) ], and 994 transgenes were connected in a main CAD regulatory gene network acting across all seven tissues (3), inferred using a causal inference test (26) . (Fig. 2) . The trans-genes in this network were enriched with genes previously associated with CAD and atherosclerosis (Fisher's test, 1.54-fold; P = 8 × 10 -10 ) (table S11). Sharing of cis/transgenes downstream of complex disease risk loci also emerged for other CMDs and AD (3-16, 24) ( fig. S40 ). In fact, we identified 33 cis-genes regulated by risk SNPs across all CMDs, including CAD and AD, acting as key drivers in a pan-disease cis/trans-gene regulatory network (Fig. 3A) . Among CMDs, cis/trans-genes of GWAS risk SNPs for blood lipid levels (5) emerged as central (Fig. 3B) where tissue-specific downstream effects were, besides LIV (46 cis-and 150 transgenes), observed in the fat tissues (SF, 45 cis-and 372 trans-genes; VAF, 38 cis-and 465 transgenes) ( fig. S41 and table S11 ). Visceral abdominal fat examples included ABCA8/ABCA5 (rs4148008) associated with 36 downstream trans-genes in VAF and HDL (high-density lipoprotein); EVI5 (rs7515577) associated with 32 VAF trans-genes and total cholesterol; and STARD3 (rs11869286) associated with 7 VAF trans-genes and HDL. In addition, the cis-gene TMEM258 (rs174546) with 22 trans-genes in abdominal fat surfaced as a parallel/alternative regulatory site of plasma low-density lipoprotein (LDL) to the proposed FADS-1,2,3 in LIV (5) (fig. S41 ). Other risk SNPs with VAF-specific cis-genes had few or even no trans-genes ( fig. S41 ). For example, two risk SNPs-rs11206510 for CAD and rs12046679 for LDL cholesterol level (3, 5)-regulate PCSK9 in VAF, not in LIV (Fig. 4, A and B) . The VAF specificity of these eQTLs PCSK9 was confirmed in an independent gene expression data set from morbidly obese patients (28) (Fig. 4C and fig.  S30 ), suggesting that PCSK9 is secreted from VAF into the portal vein to affect hepatic LDL receptor degradation, LDL plasma levels, and risk for CAD (29) . Interestingly, and as previously suggested (30), we observed that STARNET patients in the upper, compared to the lower, 5th to 20th percentiles of waist-hip ratio (i.e., patients with and without "male fat") had higher levels of circulating PCSK9 (Fig. 4D) and LDL/ HDL ratio (Fig. 4E) .
STARNET provides new insights into tissuespecific gene-regulatory effects of disease-associated risk SNPs identified by GWAS, as exemplified by abdominal fat for blood lipids, and will be a complementary resource for exploring GWAS findings moving forward. Furthermore, STARNET also revealed unexpected sharing of cis-and trans-genes downstream of risk loci for CMDs across both tissues and diseases. We anticipate that the identified cis/trans-gene regulatory networks will help elucidate the complex downstream effects of risk loci for common complex diseases, including possible epistatic effects that could shed light on the missing heritability of CMD risk. Given the detailed phenotypic data on STARNET patients, we can begin to identify how genetic variability interacts with environmental perturbations across tissues to cause pathophysiological alterations and complex diseases. Fig. 3 . Cis-and trans-gene regulation across CMDs and Alzheimer's disease. (A) A pan-disease risk SNP cis/trans-gene regulatory network. Thirtysix top key disease drivers, including 33 cis-genes for risk SNPs identified for CMDs including CAD and AD by GWAS (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 24) , were identified as having >100 downstream genes in any disease-specific network or belonging to the top five key drivers in the main regulatory gene network for each disease (table  S11) . Edge thickness reflects how frequent an edge is part of the shortest path between all pairs of network nodes. Node size reflects the number of downstream nodes in the network. RA, rheumatoid arthritis; UC, ulcerative colitis. (B) Cis-and trans-gene regulation across disease-tissue pairs. Nodes represent unique diseasetissue pairs. Edges occur when a cis-gene in one node has downstream transgenes present also in another node. Edge thickness defined as in (A). Node size reflects its centrality in the network: The position of the nodes in the network (i.e., layout) was derived from an edge-weighted spring layout algorithm.The "weight" is defined as the number of trans-genes that have a connection from the upstream node's cis-genes, normalized by the total number of trans-genes between two connecting nodes, with the result that highly connected nodes are positioned in the center of the network. is accessible through the Database of Genotypes and Phenotypes (dbGAP). ; 10th, P = 1.9 × 10 -11
; 15th, P = 5.9 × 10 -5 ; 20th, P = 0.004. LDL/HDL ratio: 5th, P = 0,007; 10th, P = 0.001; 15th, P = 0.0005; 20th, P = 0.0009.
